Royalty Report: Cancer, Drugs, Disease – Collection: 367327

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14

Primary Industries

  • Cancer
  • Drugs
  • Disease
  • Therapeutic
  • Biotechnology
  • Drug Discovery
  • DNA
  • Pharmaceuticals
  • Antibody
  • Medical
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 367327

License Grant
In consideration of the equity in the Canadian Licensee, the royalty payments reserved herein, and the covenants on the part of the Licensee contained herein, the Canadian University hereby
(a)           grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement;  and
(b)           grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.

License Property
Technology relating to antisense oligonucleotide therapy for the treatment of prostate cancer and other cancers.

U.S. Provisional filed July 19, 1999 – Serial No. 60/144,495
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone–Regulated Tumors

Full U.S. application flied July 19, 2000 – Serial No. 09/619,908
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

PCT filed July 19, 2000 – Serial No. PCT/CA00/00853
Inventors Martin Gleave and Hideaki Miyake
Antisense Therapy for Hormone-Regulated Tumors

Field of Use
Field of use is for the treatment of prostate cancer and other cancers.

OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.

IPSCIO Record ID: 367329

License Grant
In consideration of the equity in the Licensee, the royalty payments reserved herein, and the covenants on the part of the Canadian Licensee contained herein, the Canadian University hereby
(a)           grants to the Licensee an exclusive worldwide license to use and sublicense the Technology, any University Improvements and Confidential Information on the terms and conditions hereinafter set forth during the term of this Agreement;  and
(b)           grants to the Licensee an exclusive worldwide license to use and sublicense to manufacture, distribute, have distributed, sell and have sold, Products on the terms and conditions hereinafter set forth during the term of this Agreement.

The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any University Improvements with the prior written consent of the University, which consent shall not be unreasonably refused.

License Property
Technology  any and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, prior to the Date of Commencement by the University or the Licensee relating to, and including the technology described hereto, as amended from time to time, including, without limitation, all research, data, specifications, instructions, manuals, papers or other materials of any nature whatsoever, whether written or otherwise, relating to same.

98-083
U.S. Provisional filed February 26, 1999, – Serial No. 60/121,726
Inventors Martin Gleave, Hideaki Miyake and Colleen Nelson
Antisense Therapy for Prostate Cancer

PCT flied February 25, 2000 – Serial No. PCT/US00/0487
(designating U.S. and all other countries)
Inventors Martin Gleave, Paul Rennie, Hideald Miyake and Colleen Nelson
TRPM~2 Antisense Therapy

00-095
U.S. Provisional flied September 28, 2000 – Serial No. 60/236,301
Inventors Martin Gleave, H!deaki Miyake, Paul Rennie, Colleen Nelson and Toby Zellweger
chemosensitization of a Human Renal Cell Cancer Model by Antisense TRPM-2
Oligodeoxynucleotides both In Vitro and In Vivo

00-095/ 98-083
– US ClP based on the 98-083 US application (#09/913,325 – see above) and also claims the benefit of the 00-095 provisional (# 60/263,301).

Product(s)  goods manufactured in connection with the use of all or some of the Technology and/or any Improvements.

Field of Use
Field of use is for the treatment of prostate cancer and other cancers.

OGX-011 is focused on reducing clusterin production to enhance treatment sensitivity and delay tumor progression in patients who have not fully developed treatment resistance and to restore treatment sensitivity in patients who have developed treatment resistance. Clusterin is a cell survival protein that is over-produced in several cancer indications in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy. Increased clusterin production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, renal, pancreatic, anaplastic large cell lymphoma and colon cancers and melanoma. Increased clusterin production is linked to faster rates of cancer progression, treatment resistance and shorter survival duration.

IPSCIO Record ID: 203444

License Grant
The Canadian Licensor grants to the Israeli Licensee an exclusive, even as to Licensor, right and license throughout the Territory, with the right to grant sublicenses, under the Licensor Intellectual Property
– to Develop, have Developed, make, have made, and use the Licensed Compound and Licensed Product in the Field, and
– to sell, offer for sale, register, Commercialize and otherwise exploit the Licensed Product in the Field; provided that notwithstanding the exclusive rights granted to Licensee in the foregoing grant, Licensor shall retain the limited right to use the Licensor Intellectual Property to the extent necessary to perform its express obligations under this Agreement, including the Clinical Development Plan,  to conduct the Licensor Clinical Studies,  subject to the approval of the Joint Steering Committee, and as otherwise agreed to in writing by the Parties.

The exclusivity of the sublicense granted under such Licensor Intellectual Property is subject to the applicable non-exclusivity terms in the another Agreement.

Included with this agreement is also a non-exclusive, non-sublicensable, except to subcontractors as permitted under this Agreement, solely to permit such subcontractors to perform Licensors assigned responsibilities under the Clinical Development Plan, royalty-free, fully-paid right and license, by Licensee to Licensor under the Licensee Know-How and Licensee Patent Rights, solely to the extent necessary to conduct the activities assigned to Licensor by the Joint Steering Committee under the Clinical Development Plan.

License Property
The licensed property includes
TRPM-2 Antisense Therapy;
TRPM-2 Antisense Therapy and Combination composition;
TRPM-2 Antisense Therapy Using ai Oligonucleotide Having 2-0-(2- Methoxy)Ethyl Modifications Compound;
Chemo-and radiation-sensitization or cancer by antisense TRPM-2 oligodcoxynucleotides;
Treatment of Melanoma by Reduction in Clusterin Levels;
Clusterin antisense therapy for treatment of cancer;
Treatment of Cancer By Perturbation of Clusterin Levels;
Human Type 2 RNASE H;
Gapped Oligonucleotides, Directed to Gapmer and Hemimer Compounds with 2-O-ALKYL modifications;
2-O-Modified Nucleosides and Phosphoramidites; and others.

The collaboration agreement is for developing and commercializing OGX-011. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance. OGX-011 is expected to be used as adjunct therapy to enhance the effectiveness of chemotherapy and has shown promising results when added to currently available chemotherapies in several tumor types addressing a significant unmet medical need.

Field of Use
The Field means the prevention, diagnosis or treatment of any disease or medical condition in humans.  Specific fields addressed in the patents include prostate cancer cells, human renal cell cancer (RCC) cells and some breast cancer cells.

IPSCIO Record ID: 97556

License Grant
This letter agreement  memorializes the terms of the settlement of the Lawsuit reached between the Licensor and the Licensee regarding the product custirsen and other antisense inhibitors.
License Property
Product –  custirsen and certain other antisense inhibitors. Antisense therapy is a form of treatment for genetic disorders or infections.

Custirsen is an experimental drug that is designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration

IPSCIO Record ID: 367328

License Grant
Canadian University grants to the Canadian Licensee a worldwide, exclusive license to use and sublicense the Technology, University Improvements and any Joint Improvements and to manufacture, have made, distribute, and sell the Products on the terms and conditions set out in this Agreement.

The license granted under this Agreement is granted only to the Licensee and not to any Affiliated Companies. The Licensee will not cross-license the Technology or any Improvements without the prior written consent of University, which consent will not be unreasonably withheld.

The Licensee will not grant sublicenses of the Technology, University Improvements or any Joint Improvements to Affiliated Companies or other third parties without the prior written consent of University which consent will not be unreasonably withheld.

License Property
The technology relates to Hsp27 antisense and its use in the treatment of cancer.

Technology  means the Patents and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, before the Effective Date by University or the Licensee relating to, and including, the technology and materials described, as amended from time to time, including, without limitation all related research, data, specifications, instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, and University’s Confidential Information.
U.S. Provisional filed
April 18, 2003, Serial No.
60/463,952 Hsp27 Antisense to Treat Prostate and other Solid Tumours.

Patents mean collectively the rights in and to any and all inventions which are disclosed in the U.S., Canadian and foreign patents and patent applications identified and all
(i)            counterparts, continuations, divisionals, continuations-in-part, continuing prosecution applications, and requests for continued examinations, extensions, term restorations, renewals, reissues, re-examinations, or substitutions thereof;
(ii)           corresponding international patent applications;
(iii)          corresponding foreign patent applications, including supplementary protection certificates and other administrative protections; and
(iv)          international and foreign counterpart patents resulting therefrom, all of which will be deemed added, from time to time.
U.S. Provisional filed October 2, 2002, Serial
No. 60/415,859 Hsp27 Antisense to Treat Prostate and other Solid Tumours.

Product(s) means goods or services manufactured or provided in connection with the use of all or some of the Technology and/or any Improvements.

Field of Use
Field of use is for the treatment of cancer relating to Hsp27 antisense technology.

IPSCIO Record ID: 367330

License Grant
Licensor hereby grants to Canadian Licensee (a) an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and (b) a non-exclusive, worldwide license under the Licensor Core Technology Patents, both licenses solely to develop, make, have made, use, sell, offer for sale, have sold and import Products. The licenses granted to Licensee are sublicensable only in connection with a license of Products to a Third Party for the continued development and commercialization of Products in accordance with the terms of this Agreement.
License Property
Product means a pharmaceutical preparation comprising any single antisense inhibitor generated under the Project Plan which down regulates IGFBP-5 and/or IGFBP-2. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each antisense inhibitor which constitutes the active pharmaceutical ingredient in each Product.

IGFBP-5 means the gene target Insulin-like Growth Factor Binding Protein 5.

IGFBP-2 means the gene target Insulin-like Growth Factor Binding Protein 2.

Product-Specific Technology means any discovery, device, process, method of use, composition, or formulation, whether or not patented or patentable, which is made or Controlled solely by Licensor or Licensee, or jointly by Licensor and Licensee, prior to the Effective Date or during the Term of this Agreement, and which relates only to the gene targets down regulated by a Product.

The compound is the first bi-specific antisense inhibitor, a single-stranded antisense drug designed to inhibit the production of two proteins simultaneously, to enter into preclinical development. OGX-225 targets both insulin-like growth factor binding protein- 5 (IGFBP-5) and insulin-like growth factor binding protein-2 (IGFBP-2), two molecules involved in the development of metastatic disease in hormone- regulated tumors such as prostate and breast cancers. Specific financial terms of the deal were not disclosed.

Field of Use
Field of use is for cancer therapies that address treatment resistance in cancer patients.

OGX-225 could prove effective as a therapeutic to prevent progression of prostate cancer and other tumor types.

The therapies are focused on reducing the production of both insulin-like growth factor binding protein-2 (IGFBP-2) and insulin-like growth factor binding protein-5 (IGFBP-5) with a single product to enhance treatment sensitivity and delay tumor progression in patients who are resistant to hormone ablation therapy. In the treatment of tumors that require hormones for growth, clinicians use hormone ablation therapy to inhibit the production of the primary hormone (e.g. testosterone or estrogen) required for tumor growth. While tumors often regress initially following hormone ablation therapy IGFBP-2 or IGFBP-5 make available to the tumor an alternate hormone, insulin-like growth factor-1, or IGF-1, that facilitates continued tumor growth. By inhibiting the production of IGFBP-2 and IGFBP-5, the tumors access to IGF-1 is reduced and tumor growth is delayed.

IPSCIO Record ID: 314354

License Grant
By this amendment, the Parties now proceed with unilateral development of OGX-011 and Products.  As of the Amendment Effective Date, the original Collaboration is terminated.

Licensor grants the Canadian Licensee a worldwide, nonexclusive license, with the right to grant sublicenses, under the Licensor Core Technology, Core Technology Patents, Manufacturing Technology and Manufacturing Patents to research, develop, make, have made, use, gain regulatory approval, commercialize, sell, offer for sale, have sold, export and import OGX-011 and Products for all uses.

For Development, Commercialization and Regulatory Responsibilities, Licensee will have sole responsibility, including without limitation sole responsibility for all funding, resourcing and decision making, for all further development and commercialization with respect to OGX-011 and Products.

License Property
Licensor is discovering and developing RNA-targeted therapeutics, and have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics.

OGX-011 is a second generation antisense inhibitor of Clusterin.  Clusterin means the gene target, official symbol CLU, which is also referred to as Testosterone Repressed Prostatic Message -2 (TRPM-2), and Sulphated Glycoprotein2 (SGP-2).

Licensors Core Technology includes the patents and excludes the Manufacturing Technology and Product-Specific Technology.

Field of Use
Licensee is a development stage enterprise committed to the development and commercialization of new cancer therapies. The product candidates OGX-011, OGX-427 and OGX-225 focus on mechanisms of treatment resistance in cancer patients and address treatment resistance by blocking the production of specific proteins which it believes promote survival of tumor cells and are over-produced in response to a variety of cancer treatments.

IPSCIO Record ID: 372584

License Grant
Licensor grants a non-exclusive license, including the right to sublicense solely to Affiliates of Licensee, in the Territory under Licensor Use Patent Claims which are determined to include Infringing Claims for use in connection with Covered ODNs outside the Field to the extent otherwise not prohibited by this Agreement.

Licensor grants a non-exclusive license, including the right to sublicense to Permitted Sublicensees, in the Territory under Licensor Process Patent Claims for use in connection with the manufacture of Covered ODNs.

For the Research license,  Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term; provided that Licensee shall not have any rights to use the Licensor Technology for the sale or manufacture for sale of products or processes.

For Licensees Commercialization Rights, Licensee shall have the right to elect, upon notice to Licensor, to market the Product for the Licensees Indication to Specialty Dermatologists as provided.

License Property
The Licensed Product means any Product, Combination Product, Vaccine Product, Research Product, Research Combination Product or Research Vaccine Product.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensee.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Intermediate indications mean all treatment non-Hodgkins lymphoma and prostate cancer (except for Japan), all treatment of Ovarian cancer, third-line treatment of breast cancer or later treatment of breast cancer,  second-line or later treatment of NSCLC, second-line or third-line  treatment of colorectal cancer.

Minor indication means all treatment of melanoma,  T cell lymphoma, renal cell carcinoma, pancreatic cancer, hematological malignancies (other than non-Hodgkins lymphoma), bladder cancer, uterine cancer, cervical cancers and any other cancers in the field.

Licensees Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Field of Use
The field of use includes the treatment, control or prevention of cancer in humans.

Licensee owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

IPSCIO Record ID: 256873

License Grant
The Taiwanese Licensor hereby grants sole licensing rights to Licensee, a shareholder, in the Field and in the Territory under the Intellectual Property, Confidential Information, Data and Trademark, to develop Product.
License Property
Drug and therapeutic use of five products BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia
The new drug products that originate from Maitake Combination Therapy. The three drugs licensed from BriVision to Rgene are ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy.
Field of Use
Maitake Combination Therapy for indications including but not limited to the following breast cancer, brain tumor, hepatocellular carcinoma, pancreatic cancer, renal cell carcinoma, nasopharyngeal carcinoma, prostate cancer, cervix cancer, oral/ pharynx/larynx cancer, lung cancer, leukemia, myeloma, lymphoma, gastric cancer, thyroid cancer, esophageal cancer, gastric cancer, small intestine cancer, large intestine/colon/rectal cancer, ovary cancer, skin cancer, head and neck, soft tissue sarcoma, bone tumor, bladder cancer, and cholangiocarcinomab.”

IPSCIO Record ID: 367331

License Grant
Licensor hereby grants to Canadian Licensee (a) an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology to research, develop, make, have made, use, sell, offer for sale, have sold and import Products, (b) a non-exclusive, worldwide license under the Licensor Core Technology Patents, solely to research develop, make, have made, use, sell, offer for sale, have sold and import Products and (c) a non-exclusive, worldwide license under the Licensor Core Technology Patents solely to research MOE Gapmers generated under the Research Plan that modulate Collaboration Gene Targets. The licenses granted to Licensee are sublicensable only in connection with a license of a Product to one or more Third Parties for the continued development and commercialization of Products in accordance with the terms of this Agreement.  This license will automatically terminate with respect to any Product that modulates a Collaboration Gene Target that has been substituted and replaced by another gene target.
License Property
MOE Gapmer means a single stranded antisense phosphorothioate oligonucleotide of 15-30 nucleotides wherein all of the backbone linkages are modified by adding a sulfur at the non-bridging oxygen (phosphorothioate) and a stretch of at least 10 consecutive nucleotides remain unmodified (deoxy sugars) and the remaining nucleotides contain an O´-methyl O´-ethyl substitution at the 2´ position.

Collaboration Gene Target means Target Slot and any gene target occupying such a slot. Licensee will have a pool (the “Target Pool”) containing up to 2 slots for which Licensee can designate certain gene targets for collaborative research, development and commercialization under this Agreement.

Product means a pharmaceutical preparation comprising any single MOE Gapmer generated under the Project Plan which (i) down regulates a Collaboration Gene Target and (ii) Licensee has provided Licensor with written notice designating such MOE Gapmer as a development candidate.

Product-Specific Technology Patents means all Patents that claim and only to the extent that they claim Product-Specific Technology.

Product-Specific Technology means any discovery, device, process, method of use, composition, formulation, data or information, whether or not patented or patentable, which is made or Controlled solely by Licensor or Licensee, or jointly by Licensor and Licensee, prior to the Effective Date or during the Term of this Agreement, and which relates only to the gene targets down regulated by a Product or in the case of a Discontinued Product, such Discontinued Product.

Licensor Core Technology Patents means Patents Controlled by Licensor on the Effective Date that are necessary for the development and commercialization of the Product, but does not include (A) Licensor’ Product-Specific Technology Patents, or (B) Patents Controlled by Licensor that claim, and only to the extent that they claim, (i) manufacturing and analytical technologies, (ii) formulation and delivery technologies, (iii) RNAi technologies, (iv) microRNA technologies, and (v) other chemical modifications or motifs besides the MOE Gapmer chemistry.

Joint Patents means all Patents that claim, and only to the extent that they claim, Joint Technology.

OGX-011 is a second-generation antisense inhibitor of clusterin and represents the first second-generation anticancer antisense drug based on Licensor's proprietary chemistry to enter clinical development.  Clusterin is a cell-survival protein that is over-expressed in many cancers and is associated with treatment resistance and poor clinical outcome.

Field of Use
Field of use is for the treatment of Cancer.

In preclinical animal studies, OGX-011 improved the potency of traditional chemotherapies by more than 10-fold in prostate cancer with no increase in toxicity. OGX-011 also significantly delayed disease progression in many tumor model systems including in prostate, non-small cell lung, bladder and renal.

IPSCIO Record ID: 27866

License Grant
In 2001 an original License between two co-discovering companies relative to the cancer treatment OGX-011 (antisense therapeutic) was executed.

Update  in December 2009 the Licensee entered into a global licensing and partnership agreement with a third company.  The Licensor in the transaction above continues to receive payments from the secondary License too.

License Property
OGX-011 is a targeted antisense agent to clusterin that predominantly acts as an anti-apoptotic protein to protect cancer cells from cellular.
Field of Use
OGX-011 is an experimental drug that has been shown to increase the effectiveness of chemotherapy in several kinds of tumors, including prostate cancer.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.

IPSCIO Record ID: 26619

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
The Licensor desires to sublicense of such Patent Rights and Know-how in order to commercialize 06-Benzyl guanine (06BG) and related technologies for the treatment of cancer.

O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents.  In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma.   A Phase II development program began in 1999.  O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents.  O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer.  The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents.  The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.

The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.

Field of Use
The rights granted apply in all fields of use relating to technologies for the treatment of cancer.

IPSCIO Record ID: 251135

License Grant
The parties entered into a nonexclusive license agreement on the patented ChemoFx technology.
License Property
ChemoFx ®, is a proprietary drug response marker which measures an individuals malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. Newly published prospective data demonstrates a 14 -month improvement in overall survival (OSI and improved progression free survival (PFS) when ovarian cancer patients are treated with responsive therapies as indicated by ChemoFx ®.
Field of Use
The ChemoFx assay is an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.